Literature DB >> 31577604

Complications associated with immunotherapy for brain metastases.

Thuy T Tran1,2, Lucia B Jilaveanu1,2, Antonio Omuro1,2,3, Veronica L Chiang1,2,4, Anita Huttner2,5, Harriet M Kluger1,2.   

Abstract

PURPOSE OF REVIEW: Median survival after the diagnosis of brain metastases has historically been on the order of months. With the recent development of immune checkpoint inhibitors, intracranial activity and durable responses have been observed in brain metastases on multiple phase 2 clinical trials, which have primarily been conducted in patients with melanoma. Immune-related adverse events related to checkpoint inhibitor therapy of brain metastasis can present unique challenges for the clinician and underscore the need for a multidisciplinary team in the care of these patients. The goal of this review is to address the current knowledge, limitations of understanding, and future directions in research regarding immune therapy trials and neurologic toxicities based on retrospective, prospective, and case studies. RECENT
FINDINGS: Immune therapy has the potential to exacerbate symptomatic edema and increase the risk of radiation necrosis in previously irradiated lesions. Neurologic toxicities will likely increase in prevalence as more patients with brain metastatic disease are eligible for immune therapy.
SUMMARY: An improved understanding and heightened awareness of the unique neurologic toxicities that impact this patient group is vital for mitigating treatment-related morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31577604      PMCID: PMC7398556          DOI: 10.1097/WCO.0000000000000756

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   6.283


  46 in total

Review 1.  Capture, crawl, cross: the T cell code to breach the blood-brain barriers.

Authors:  Britta Engelhardt; Richard M Ransohoff
Journal:  Trends Immunol       Date:  2012-08-25       Impact factor: 16.687

2.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

Authors:  Jonathan P S Knisely; James B Yu; Jaclyn Flanigan; Mario Sznol; Harriet M Kluger; Veronica L S Chiang
Journal:  J Neurosurg       Date:  2012-06-15       Impact factor: 5.115

3.  Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

Authors:  J A Takahashi; M Fukumoto; K Igarashi; Y Oda; H Kikuchi; M Hatanaka
Journal:  J Neurosurg       Date:  1992-05       Impact factor: 5.115

4.  Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.

Authors:  Zachary A Kohutek; Yoshiya Yamada; Timothy A Chan; Cameron W Brennan; Viviane Tabar; Philip H Gutin; T Jonathan Yang; Marc K Rosenblum; Åse Ballangrud; Robert J Young; Zhigang Zhang; Kathryn Beal
Journal:  J Neurooncol       Date:  2015-08-26       Impact factor: 4.130

5.  Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Authors:  Justine V Cohen; Ahmed K Alomari; Alexander O Vortmeyer; Lucia B Jilaveanu; Sarah B Goldberg; Amit Mahajan; Veronica L Chiang; Harriet M Kluger
Journal:  Cancer Immunol Res       Date:  2015-12-23       Impact factor: 11.151

6.  Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma.

Authors:  Sara Valpione; Marco Zoccarato; Raffaele Parrozzani; Jacopo Pigozzo; Bruno Giometto; Francesco Laveder; Camillo Aliberti; Vanna Chiarion-Sileni
Journal:  J Neurol Sci       Date:  2013-08-30       Impact factor: 3.181

Review 7.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

8.  Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans.

Authors:  K L Black; J T Hoff; J E McGillicuddy; S S Gebarski
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

9.  Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.

Authors:  Shelly Lwu; Pablo Goetz; Eric Monsalves; Mandana Aryaee; Julius Ebinu; Norm Laperriere; Cynthia Menard; Caroline Chung; Barbara-Ann Millar; Abhaya V Kulkarni; Mark Bernstein; Gelareh Zadeh
Journal:  Oncol Rep       Date:  2012-11-14       Impact factor: 3.906

Review 10.  Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases.

Authors:  Hany Soliman; Sunit Das; David A Larson; Arjun Sahgal
Journal:  Oncotarget       Date:  2016-03-15
View more
  10 in total

Review 1.  The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC.

Authors:  Ji Li; Min Wang; Shuhui Xu; Yuying Li; Jiatong Li; Jinming Yu; Hui Zhu
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 2.  Regional Responses in Radiation-Induced Normal Tissue Damage.

Authors:  Daniëlle C Voshart; Julia Wiedemann; Peter van Luijk; Lara Barazzuol
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

3.  Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.

Authors:  Mani Ratnesh S Sandhu; Veronica L Chiang; Thuy Tran; James B Yu; Sarah A Weiss; Sarah B Goldberg; Mariam S Aboian; Harriet M Kluger; Amit Mahajan
Journal:  J Neurooncol       Date:  2021-08-05       Impact factor: 4.130

Review 4.  Overcoming delivery barriers in immunotherapy for glioblastoma.

Authors:  Yuan Rui; Jordan J Green
Journal:  Drug Deliv Transl Res       Date:  2021-05-30       Impact factor: 4.617

5.  Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions.

Authors:  Young-Sil An; Se-Hyuk Kim; Tae Hoon Roh; So Hyun Park; Tae-Gyu Kim; Jang-Hee Kim
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

Review 6.  Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.

Authors:  Michael T Milano; Jimm Grimm; Andrzej Niemierko; Scott G Soltys; Vitali Moiseenko; Kristin J Redmond; Ellen Yorke; Arjun Sahgal; Jinyu Xue; Anand Mahadevan; Alexander Muacevic; Lawrence B Marks; Lawrence R Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-11       Impact factor: 8.013

Review 7.  Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.

Authors:  Vassilis Genoud; Denis Migliorini
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

Review 8.  Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects.

Authors:  Selia Chowdhury; Mehedi Hasan Bappy; Santiago Clocchiatti-Tuozzo; Srinidhi Cheeti; Samia Chowdhury; Vraj Patel
Journal:  Cureus       Date:  2021-12-22

Review 9.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937

10.  Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells.

Authors:  Thuy T Tran; Chetan K Rane; Christopher R Zito; Sarah A Weiss; Shlomit Jessel; Liliana Lucca; Benjamin Y Lu; Victor O Oria; Adebowale Adeniran; Veronica L Chiang; Sacit Bulent Omay; David A Hafler; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.